Empaveli (Pegcetacoplan)
- Medicine Name: Empaveli
- Generic Name: Pegcetacoplan
- Dosage Form & Strength: Injection: 1,080 mg/20 mL (54 mg/mL) in a single-dose vial
- Manufactured By: Apellis Pharmaceuticals, Inc.
Medical Uses
Empaveli is a complement inhibitor used for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Recommended Dosage: Patients should be vaccinated against encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B at least a couple of weeks before initiating Empaveli 1,080 mg/20 mL (54 mg/mL) therapy as per the current ACIP guidelines.
Two weeks of antibacterial drug prophylaxis should be provided to patients if Pegcetacoplan must be initiated promptly and vaccines are given less than 2 weeks prior to starting therapy with Empaveli.
The recommended dose is 1,080 mg administered by subcutaneous infusion twice weekly via a commercially available infusion pump with a reservoir of at least 20 mL.
Administer this medication as promptly as possible after a missed/skipped dose. Resume the regular dosing schedule after administration of the skipped/missed dose.
Warning & Precautions
- Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) may occur in those treated with Empaveli. In case of a severe hypersensitivity reaction (including anaphylaxis), discontinue this infusion promptly, institute apt treatment, per standard of care, and evaluate until signs/symptoms are resolved.
- The use of Pegcetacoplan 1,080 mg/20 mL (54 mg/mL) may predispose individuals to severe, life-threatening, or fatal infections caused by encapsulated bacteria including Neisseria meningitidis types A, C, W, Y, and B, Streptococcus pneumoniae, and Haemophilus influenzae type B (Hib).
- For those without known history of vaccination, administer needed vaccines at least a couple of weeks prior to receiving the first dose of Pegcetacoplan. If immediate therapy with Pegcetacoplan is indicated, administer the required vaccine as quickly as possible and provide patients with a couple of weeks of antibacterial medicine prophylaxis.
- Precisely monitor patients for early signs/symptoms of severe infection and assess patients promptly in case an infection is noticed. Known infections must be promptly treated. Severe infection may quickly become hazardous or fatal if not noticed and treated early. Consider discontinuation of empaveli in those who are undergoing therapy for severe infections.
- After discontinuing treatment with empaveli 54 mg/mL, closely monitor for signs/symptoms of hemolysis, identified by elevated LDH levels along with sudden reduction in PNH clone size or hemoglobin, or reappearance of symptoms such as abdominal pain, dyspnea, fatigue, hemoglobinuria, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction.
- Evaluate any respective patient who discontinues Pegcetacoplan for at least 8 weeks in order to detect hemolysis and certain other reactions. In case hemolysis, including elevated LDH, occurs after discontinuation of Pegcetacoplan, consider restarting treatment with this medicinal product.
- Women who are able to become pregnant must use an appropriate method of birth control (contraception) throughout the treatment with Pegcetacoplan and for 40 days after the last dose. Women should not breastfeed during therapy and for 40 days after the last dose.
Documentation & Availability
What documents are required to import EMPAVELI to India?
EMPAVELI (pegcetacoplan) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is EMPAVELI available in India?
EMPAVELI (pegcetacoplan injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability of Empaveli in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
EMPAVELI can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of EMPAVELI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Number: +91-7575883015 or write us at sshealthcare1012@gmail.com for Empaveli 54 mg/mL mg price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the EMPAVELI (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Empaveli®?
Pegcetacoplan is Generic Name for the trade name drug Empaveli®.
What is the Manufacturer Name of Empaveli®?
Empaveli® is manufactured by Apellis Pharmaceuticals, Inc.
Is Empaveli® approved by the FDA?
Yes, Empaveli® is approved by the FDA. Date of first/initial approval: May 14, 2021.
Where can I get Empaveli® at the best price in India?
To get the best Empaveli price in India, kindly contact S S Healthcare (a WHO GDP & ISO 9001 : 2008 certified company). For Empaveli®, a valid medical prescription is required from your treating doctor.
What is the dosage and form of Empaveli® supplied?
Empaveli® is supplied as Injection: 1,080 mg/20 mL (54 mg/mL) in a single-dose vial for subcutaneous use.
What are the most common side effects with Empaveli®?
The most common side effects with Empaveli® include: viral infection, injection-site reactions, abdominal pain, infections, diarrhea, respiratory tract infection, and fatigue.
How much does Empaveli® cost in India?
Empaveli cost in India can vary. In order to procure this PNH medication authentically, you can Call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Empaveli®?
Store vials of Empaveli at 2-8°C (36-46°F) in the original carton in order to protect from light. Never use beyond the expiration date stamped on the carton.
Is it safe to buy Empaveli® online from India?
Yes, You can buy empaveli in India at the best price from the S S Healthcare if Empaveli® has not been approved or is not available in your country.
What are the Highlights of prescribing information for Empaveli®?
Click Here to download full Empaveli prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
